Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

OBJECTIVES: Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses high levels of programmed death ligand-1 (PD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Min, Lou, Yanyan, Pellissier, James, Burke, Thomas, Liu, Frank Xiaoqing, Xu, Ruifeng, Velcheti, Vamsidhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548835/
https://www.ncbi.nlm.nih.gov/pubmed/28620848
http://dx.doi.org/10.1007/s40273-017-0527-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548835/
https://www.ncbi.nlm.nih.gov/pubmed/28620848
http://dx.doi.org/10.1007/s40273-017-0527-z

Ejemplares similares